Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) has announced that its Compensation Committee has approved an equity award for a new employee under its 2023 Inducement Plan. The award, granted on March 15, 2025, consists of restricted stock units and stock options totaling 72,882 shares of Emergent common stock. This equity grant was made in accordance with the NYSE Listing Rule 303A.08 employment inducement award exception. The awarded shares will fully vest on March 15, 2026, contingent upon the employee's continued service through the vesting date.

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").

The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

How many shares were granted in Emergent BioSolutions (EBS) new employee equity award?

The equity award consists of 72,882 shares of Emergent common stock, including both restricted stock units and stock options.

When will the EBS employee equity award vest?

The equity award will fully vest on March 15, 2026, provided the employee maintains continuous service until then.

What is the purpose of Emergent BioSolutions' 2023 Inducement Plan?

The 2023 Inducement Plan is used to grant equity awards to newly hired employees as employment inducements under NYSE rules.

Under which NYSE rule was the EBS equity award granted?

The equity award was granted under the employment inducement award exception to NYSE Listing Rule 303A.08.